@mskcancercenter.bsky.social
Where you're treated first, matters. To make an appointment: 833-637-6698
@mskcancercenter.bsky.socialCongrats to MSK's most recent awards and appointments, including Dr. Zsofia Stadler for being appointed Chief of MSK’s Clinical Genetics Service, Dr. Seungjae Lee for being named a finalist for the 2026 Blavatnik Regional Awards for Young Scientists, and more: https://bit.ly/4zjtfSo
@mskcancercenter.bsky.social🎉 Congratulations to MSK radiation oncologists Dr. Christopher Barker, Dr. Daphna Gelblum, and Dr. Abraham Wu on being named 2026 ASTRO Fellows, recognizing their contributions to radiation oncology! #ASTRO2026
@mskcancercenter.bsky.socialThe FDA recently approved a targeted therapy called lirafugratinib (Lyrfigtu) for people with advanced cholangiocarcinoma that has a genetic change called an FGFR2 fusion.
The clinical trial that resulted in the drug’s approval was led by MSK's Dr. Alison Schram.
@mskcme.bsky.socialReposted by @mskcancercenter.bsky.socialJoin us in NYC or virtually on Oct. 8–9 to explore advances and key questions across the continuum of #ProstateCancer care, featuring tumor boards, panel discussions, and debates with multidisciplinary experts from @mskcancercenter.bsky.social and other leading institutions. 🔗 bit.ly/Prostate2026CME
@mskeducation.bsky.socialReposted by @mskcancercenter.bsky.socialTo all #MSKPostdocs - THANK YOU for your significant contributions to the @mskcancercenter.bsky.social research community! MSK-PDA we are proud to celebrate you!
#NPAW2026
@mskcancercenter.bsky.socialThe laboratory findings potentially pave the way for new approaches against immunotherapy-resistant tumors, as well as for a host of other fibrotic and inflammatory diseases. Learn more: bit.ly/4rK5dgW
@mskcancercenter.bsky.socialMSK scientists from the Scott Lowe Lab and the Daniel Heller Lab engineered nanoparticles to target cells driving scarring around many liver and lung tumors. In mice, this reduced scarring and helped immunotherapy shrink tumors that resisted treatment.
@mskcancercenter.bsky.socialJoin MSK experts Oct. 2, at ET for a complimentary virtual symposium on multidisciplinary care for pediatric brain and spinal tumors.
Participants will hear practical updates on the latest advances in multidisciplinary neuro-oncology care. Learn more and register: https://bit.ly/4xTYrGQ
@mskcancercenter.bsky.socialThe FDA has approved the drug belzutifan in combination with lenvatinib for patients with a type of #kidneycancer called clear cell renal cell carcinoma (ccRCC).
The approval was based on a clinical trial led by Dr. Robert Motzer, a genitourinary medical oncologist at MSK. https://bit.ly/4hiaiJO
@mskcancercenter.bsky.socialComing up at #ASTRO26: MSK radiation oncologist Dr. Brandon Imber will present research on bridging radiotherapy and systemic inflammation before CAR T-cell therapy for B-cell lymphomas.
🗓️ Wednesday, September 30 | 9:15 a.m. ET
Learn more: https://bit.ly/3VCyz4K
@mskcancercenter.bsky.socialTomorrow at #ASTRO26: MSK radiation oncologist Dr. Kevin Boehm will present research using pathology images and clinical tumor sequencing from more than 60,000 patients to model cancer subtypes and molecular features.
🗓️ Wednesday, September 30 | 8:20 a.m. ET
Learn more: https://bit.ly/4ACpx7M
@mskcancercenter.bsky.socialAt #ASTRO26, MSK researchers presented studies on organ preservation and circulating tumor DNA (ctDNA) monitoring in rectal and anal cancers. Their work examines how treatment and follow-up care could be tailored to each patient.
Read about the studies and their findings: https://bit.ly/4hsBnsA
@mskcancercenter.bsky.socialComing up at #ASTRO26: MSK radiation oncologist Dr. Marsha Reyngold will present two- and three-year overall survival findings after ablative MR-guided radiotherapy for localized pancreatic cancer without surgery.
🗓️ Tuesday, September 29 | 5:20 p.m. ET
Learn more: https://bit.ly/3TnVS1F
@mskcancercenter.bsky.socialComing up at #ASTRO26: MSK radiation oncologist Dr. Sean McBride will present “Intensify, Shorten, or Personalize? Modern Approaches to Post-prostatectomy RT.”
🗓️ Tuesday, September 29 | 12:30 p.m. ET
@mskcancercenter.bsky.socialNew research from MSK shows how a metabolite boosts immune cells against cancer; adds to the understanding of how colorectal cancer spreads; and more: https://bit.ly/4z2sJbt
@mskcancercenter.bsky.socialToday at #ASTRO26: MSK radiation oncologist Dr. Alexander Goglia will present five-year outcomes from a trial of MR-guided SBRT with a focal DIL boost for intermediate-risk prostate cancer.
🗓️ Monday, September 28 | 3:10 p.m. ET
Learn more: https://bit.ly/47lXHPT
@mskcancercenter.bsky.socialComing up at #ASTRO26: MSK's Dr. George Naoum will present a validated tool that predicts the risk of invasive breast cancer recurrence for patients with N1mic disease treated with or without nodal radiotherapy.
🗓️ Monday, September 28 | 8:30 a.m. ET
Learn more: https://bit.ly/4hsThvo
@mskcancercenter.bsky.socialComing up at #ASTRO26: MSK radiation oncologist Dr. Nancy Lee will present a pooled analysis of trials studying FMISO PET-guided, lower-dose radiation for HPV-positive oropharyngeal cancer.
🗓️ Sunday, September 27 | 3 p.m. ET
Learn more: https://bit.ly/4yYOmcE
@mskcancercenter.bsky.socialComing up at #IMS26: MSK myeloma specialist & cellular therapist Dr. Sham Mailankody will discuss bispecifics in the outpatient setting during a Meet the Experts session.
🗓️ Thursday, September 24 | 12 p.m. BT / 7 a.m. ET
@mskcancercenter.bsky.socialResearchers in Dr. Agnel Sfeir’s lab at MSK identified a hidden structural weakness in rogue DNA found in aggressive cancers.
In lab studies, blocking the protein that repairs this DNA caused it to become unstable and gradually disappear from cancer cells.
Learn more: https://bit.ly/3V8pyjO
